November 1, 2023 - Pfizer

01/28/2022 – Policy Notice

01/28/2022 – Policy Update

11/01/2023 – Policy Update (08/2023)

11/01/2023 – Policy Update (10/02/2023)

Can CE get 340B pricing if they share claims data?

Yes – 340B ESP

Are system owned contract pharmacies exempted from this policy?

Yes

Can CEs with no in-house pharmacy designate a contract pharmacy for 340B pricing access?

Yes (CEs can designate 2 CPs – one for Xeljanz specifically and a specialty pharmacy for other oral oncology products affected by this policy

Drugs affected by this policy:

Xeljanz, Bosulfi, Braftovi,Daurismo, Ibrance, Inlyta, Lorbrena, Mektovi, Sutent, Talzenna and Xalkori

Policy applies to what entity types?

Policy applies to hospitals covered entities only. Federal grantees are exempted from this policy.